Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 335
- Registration Number
- NCT04763408
- Locations
- 🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇩🇪Eisai Trial Site #2, Berlin, Germany
🇩🇪Eisai Trial Site #6, Munich, Germany
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 326
- Registration Number
- NCT04723004
- Locations
- 🇨🇳
Jilin Guowen Hospital, Changchun, Jilin, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 490
- Registration Number
- NCT04720716
- Locations
- 🇨🇳
Fudan Universtiy Zhongshan Hospital, Shanghai, Shanghai, China
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 150
- Registration Number
- NCT04710641
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇸🇬National University Hospital Singapore, Singapore, Singapore
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 85
- Registration Number
- NCT04709380
- Locations
- 🇨🇳
Bo Chen, Beijing, Beijing, China
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 346
- Registration Number
- NCT04674345
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- Device: Radiofrequency ablationDrug: Trance-arterial chemoembolizationProcedure: Liver resectionDrug: Percutaneous ethanol injectionCombination Product: Combined radiofrequency ablation + percutaneous ethanol injectionDrug: Systemic chemotherapyDrug: SorafenibDietary Supplement: ViscumDrug: Symptomatic treatment
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 407
- Registration Number
- NCT04553458
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Shanghai Henlius Biotech
- Registration Number
- NCT04465734
- Locations
- 🇨🇳
Ethics committee of zhongshan hospital affiliated to fudan university, Shanghai, China
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
- Conditions
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 54
- Registration Number
- NCT04387695
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
AflacLL1901 (CHOA-AML)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.